Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
116.60
+0.05 (+0.04%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
July 16, 2021
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC
July 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
July 12, 2021
From
Merck & Co., Inc.
Via
Business Wire
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
July 12, 2021
From
Merck
Via
Business Wire
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
July 06, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
July 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29
June 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
June 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Appoints Michael Klobuchar Chief Strategy Officer
June 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
June 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
June 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress Towards Improved Birth Outcomes for All
June 18, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck to Participate in the Guggenheim Biopharma Strategy Series
June 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All
June 16, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
June 09, 2021
From
Merck & Co., Inc.
Via
Business Wire
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
June 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial
June 03, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)
June 03, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Completion of Organon & Co. Spinoff
June 03, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
June 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Third-Quarter 2021 Dividend
May 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
May 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
The Companies Tackling A Global Health Crisis
May 20, 2021
Via
FinancialNewsMedia
Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
May 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Named to 100 Best Corporate Citizens of 2021
May 18, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Climate Change
Exposures
Climate
Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing
May 13, 2021
Via
FinancialNewsMedia
Exposures
Product Safety
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
May 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Declares Record Date and Dividend for the Organon & Co. Spinoff
May 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
May 06, 2021
From
Merck
Via
Business Wire
Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
May 06, 2021
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.